Newbury Pharmaceuticals AB (publ) (NEWBRY.ST)

SEK 3.42

(-2.29%)

Total Debt Summary of Newbury Pharmaceuticals AB (publ)

  • Newbury Pharmaceuticals AB (publ)'s latest annual total debt in 2024 was - SEK , down 0.0% from previous year.
  • Newbury Pharmaceuticals AB (publ)'s latest quarterly total debt in 2024 Q4 was - SEK , down 0.0% from previous quarter.
  • Newbury Pharmaceuticals AB (publ) reported annual total debt of - SEK in 2023, down 0.0% from previous year.
  • Newbury Pharmaceuticals AB (publ) reported annual total debt of - SEK in 2022, down 0.0% from previous year.
  • Newbury Pharmaceuticals AB (publ) reported quarterly total debt of - SEK for 2024 Q3, down 0.0% from previous quarter.
  • Newbury Pharmaceuticals AB (publ) reported quarterly total debt of - SEK for 2024 Q2, down 0.0% from previous quarter.

Annual Total Debt Chart of Newbury Pharmaceuticals AB (publ) (2024 - 2021)

Historical Annual Total Debt of Newbury Pharmaceuticals AB (publ) (2024 - 2021)

Year Total Debt Total Debt Growth
2024 - SEK 0.0%
2023 - SEK 0.0%
2022 - SEK 0.0%
2021 - SEK 0.0%

Peer Total Debt Comparison of Newbury Pharmaceuticals AB (publ)

Name Total Debt Total Debt Difference
AcuCort AB - SEK NaN%
AlzeCure Pharma AB (publ) - SEK NaN%
BioGaia AB (publ) 8.8 Million SEK 100.0%
Enzymatica AB (publ) 26.1 Million SEK 100.0%
Enorama Pharma AB (publ) 436 Thousand SEK 100.0%
Gabather AB (publ) - SEK NaN%
Klaria Pharma Holding AB (publ.) 18.93 Million SEK 100.0%
Moberg Pharma AB (publ) 4.73 Million SEK 100.0%
Nanexa AB (publ) 4.03 Million SEK 100.0%
ODI Pharma AB - SEK NaN%
Orexo AB (publ) 473.8 Million SEK 100.0%
Probi AB (publ) 53.79 Million SEK 100.0%
Swedencare AB (publ) 1.65 Billion SEK 100.0%
Swedish Orphan Biovitrum AB (publ) 20.48 Billion SEK 100.0%
Toleranzia AB 850 Thousand SEK 100.0%
Vivesto AB 8.16 Million SEK 100.0%